Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

X4 Pharmaceuticals, Inc. (XFOR)

1.8   0.07 (4.05%) 11-25 13:00
Open: 1.77 Pre. Close: 1.73
High: 1.885 Low: 1.7493
Volume: 216,873 Market Cap: 125(M)

Technical analysis

as of: 2022-11-25 2:01:35 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.26     One year: 2.45
Support: Support1: 1.67    Support2: 1.39
Resistance: Resistance1: 1.93    Resistance2: 2.09
Pivot: 1.82
Moving Average: MA(5): 1.79     MA(20): 1.84
MA(100): 1.44     MA(250): 1.61
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 20.8     %D(3): 24.2
RSI: RSI(14): 48.9
52-week: High: 4.19  Low: 0.86
Average Vol(K): 3-Month: 866 (K)  10-Days: 393 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ XFOR ] has closed above bottom band by 40.2%. Bollinger Bands are 46.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.81 - 1.82 1.82 - 1.83
Low: 1.66 - 1.67 1.67 - 1.68
Close: 1.71 - 1.73 1.73 - 1.75

Company Description

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

Headline News

Tue, 08 Nov 2022
X4 Pharmaceuticals to Present at Stifel Healthcare Conference - Yahoo Finance

Thu, 03 Nov 2022
X4 Pharmaceuticals: Q3 Earnings Snapshot - Beaumont Enterprise

Wed, 26 Oct 2022
X4 Pharmaceuticals (XFOR) Appoints Mark Baldry as Chief Commercial Officer -

Fri, 07 Oct 2022
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt? - Simply Wall St

Fri, 30 Sep 2022
Is X4 Pharmaceuticals Inc (XFOR) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Tue, 27 Sep 2022
Healthcare Stocks Moving Up and Down Tuesday: ATXI, INM, SONX, XFOR, MTP, OCUL, RNA, ISPC - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 69 (M)
Shares Float 51 (M)
% Held by Insiders 1 (%)
% Held by Institutions 60.7 (%)
Shares Short 1,620 (K)
Shares Short P.Month 1,810 (K)

Stock Financials

EPS -3.45
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.89
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -43.8
Return on Equity (ttm) -145.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.18
Qtrly Earnings Growth 0
Operating Cash Flow -77 (M)
Levered Free Cash Flow -47 (M)

Stock Valuations

PE Ratio -0.53
PEG Ratio 0
Price to Book value 2
Price to Sales 0
Price to Cash Flow -1.62

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-03-13
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.